VILDAGLIPTINA / VILDAGLIPTIN

Portal Fármacos ||

Ficha Técnica de la Agemed .

Bibliografía en PUBMED en Core Clinical Journals



Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism. 2009 Apr; 94(4): 1236-43. Ahren, Bo; Schweizer, Anja; Dejager, Sylvie; Dunning, Beth E; Nilsson, Peter M; Persson, Margaretha; Foley, James E;

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Hospital practice (1995). 2011 Feb; 39(1): 7-21. Bourdel-Marchasson, Isabelle; Schweizer, Anja; Dejager, Sylvie;

Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Hospital practice (1995). 2013 Apr; 41(2): 93-107. Charbonnel, Bernard; Schweizer, Anja; Dejager, Sylvie;

Understanding the incretin effect.
The Journal of clinical endocrinology and metabolism. 2011 Apr; 96(4): 934-5. Seino, Yutaka;

Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.
Endocrinology. 2012 Dec; 153(12): 5735-45. Jessen, Lene; Aulinger, Benedikt A; Hassel, Jonathan L; Roy, Kyle J; Smith, Eric P; Greer, Todd M; Woods, Stephen C; Seeley, Randy J; D'Alessio, David A;

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.
The Journal of clinical endocrinology and metabolism. 2008 Jan; 93(1): 103-9. Mari, Andrea; Scherbaum, Werner A; Nilsson, Peter M; Lalanne, Gerard; Schweizer, Anja; Dunning, Beth E; Jauffret, Sophie; Foley, James E;

Individualising treatment for older people with diabetes.
Lancet. 2013 Aug 3; 382(9890): 378-80. Morley, John E; Sinclair, Alan;

DPP-4 inhibitors in clinical practice.
Postgraduate medicine. 2009 Nov; 121(6): 70-100. Palalau, Anna I; Tahrani, Abd A; Piya, Milan K; Barnett, Anthony H;

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Postgraduate medicine. 2013 May; 125(3): 7-20. Scheen, Andre J;

Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
The Journal of clinical endocrinology and metabolism. 2012 Oct; 97(10): 3799-806. Farngren, Johan; Persson, Margaretha; Schweizer, Anja; Foley, James E; Ahren, Bo;

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.
Lancet. 2013 Aug 3; 382(9890): 409-16. Strain, W David; Lukashevich, Valentina; Kothny, Wolfgang; Hoellinger, Marie-Jose; Paldanius, Paivi Maria;

A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors.
JAMA dermatology (Chicago, Ill.). 2013 Feb; 149(2): 243-5. Aouidad, Iman; Fite, Charlotte; Marinho, Eduardo; Deschamps, Lydia; Crickx, Beatrice; Descamps, Vincent;

Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
The American journal of the medical sciences. 2010 Aug; 340(2): 133-43. Kuritzky, Louis;

Impact of the dipeptidyl peptidase-4 inhibitor vildagliptin on glucose tolerance and beta-cell function and mass in insulin receptor substrate-2-knockout mice fed a high-fat diet.
Endocrinology. 2012 Mar; 153(3): 1093-102. Sato, Koichiro; Nakamura, Akinobu; Shirakawa, Jun; Muraoka, Tomonori; Togashi, Yu; Shinoda, Kazuaki; Orime, Kazuki; Kubota, Naoto; Kadowaki, Takashi; Terauchi, Yasuo;

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
The Journal of clinical endocrinology and metabolism. 2009 Jan; 94(1): 81-8. D'Alessio, David A; Denney, Amanda M; Hermiller, Linda M; Prigeon, Ronald L; Martin, Julie M; Tharp, William G; Saylan, Monica Liqueros; He, Yanling; Dunning, Beth E; Foley, James E; Pratley, Richard E;

Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism. 2011 Apr; 96(4): 945-54. Vardarli, Irfan; Nauck, Michael A; Kothe, Lars D; Deacon, Carolyn F; Holst, Jens J; Schweizer, Anja; Foley, James E;

Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet.
Endocrinology. 2012 Aug; 153(8): 3878-85. Apaijai, Nattayaporn; Pintana, Hiranya; Chattipakorn, Siriporn C; Chattipakorn, Nipon;

Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
Diabetes. 2009 Jan; 58(1): 243-9. Edgerton, Dale S; Johnson, Kathryn M S; Neal, Doss W; Scott, Melanie; Hobbs, Charles H; Zhang, Xia; Duttaroy, Alokesh; Cherrington, Alan D;

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism. 2008 Feb; 93(2): 459-64. Azuma, Koichiro; Radikova, Zofia; Mancino, Juliet; Toledo, Frederico G S; Thomas, Ernestine; Kangani, Cyrous; Dalla Man, Chiara; Cobelli, Claudio; Holst, Jens J; Deacon, Carolyn F; He, Yanling; Ligueros-Saylan, Monica; Serra, Denise; Foley, James E; Kelley, David E;

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
The Journal of clinical endocrinology and metabolism. 2009 Mar; 94(3): 846-52. Boschmann, Michael; Engeli, Stefan; Dobberstein, Kerstin; Budziarek, Petra; Strauss, Anke; Boehnke, Jana; Sweep, Fred C G J; Luft, Friedrich C; He, Yanling; Foley, James E; Jordan, Jens;


Subir